DaVita Inc. (DVA)

Revenue growing ~3-4% driven by modest rate increases and dialysis treatment volume stability. Fresenius Medical Care (the only direct comparable) is performing similarly. Both companies are GDP-level growers at best. There's no peer outperformance because the industry is structurally low-growth.

DaVita holds ~35% of the US dialysis market (duopoly with Fresenius at ~38%). Share has been stable for years — the market is effectively consolidated. Small independents occasionally sell to DaVita or Fresenius, providing incremental tuck-in growth. No risk of share loss but limited opportunity for share gain.

Pricing is largely determined by Medicare/Medicaid reimbursement rates (~70% of revenue). DaVita has limited ability to negotiate rates — it's a price-taker from government payers. Commercial payer rates are higher and more negotiable, but commercial mix has been declining. Pricing power is effectively zero on the government side.

DaVita is investing in home dialysis and integrated kidney care (value-based arrangements with insurers). These are important strategic pivots but early-stage. The core business model hasn't fundamentally changed in 20 years — patients come to centers 3x/week for hemodialysis. Innovation is necessary but slow.

Patients develop relationships with their care teams and prefer not to switch centers. Dialysis requires consistency — the same machine settings, vascular access management, and treatment protocols. However, switching is possible (patients can transfer), and CMS regulations ensure patients can choose their provider. Switching costs are real but not insurmountable.

Limited network effects. DaVita's scale provides geographic coverage that's valuable for patients (convenience of a nearby center), but one center doesn't become more valuable because another exists. Data from integrated kidney care programs could create modest learning advantages. Overall, weak network effects.

Dialysis centers require Medicare certification, state licensure, and compliance with extensive CMS Conditions for Coverage. This regulatory complexity creates barriers to entry. Certificate of need laws in some states directly limit competition. But the regulatory framework also constrains DaVita — reimbursement rates, quality reporting, and staffing requirements are imposed.

Building a national dialysis network requires significant capital and years of execution. The scale advantages in procurement (dialyzers, supplies), labor, and technology development are real. But dialysis center capex per unit is relatively modest ($2-3M), so a well-capitalized competitor could theoretically build centers. The barrier is more operational than capital-driven.

FY2026 estimates are roughly flat — no significant revisions in either direction. The street models 5-8% EPS growth, driven primarily by share buybacks rather than operational growth. DaVita consistently meets guidance, but the growth is financial engineering rather than fundamental improvement.

The dominant narrative is the GLP-1 disruption risk — if Ozempic/Mounjaro/Zepbound meaningfully slow diabetic kidney disease progression, the long-term dialysis patient population could shrink. This may take 10-15 years to materialize but the market is already discounting it. Every GLP-1 clinical trial headline weighs on DVA stock. The Berkshire ownership provides counterbalancing positive sentiment.

CEO Javier Rodriguez has managed the business competently and been transparent about the GLP-1 risk timeline. Capital allocation is aggressive — DaVita has bought back 40%+ of shares outstanding over the past decade. The buyback strategy works when the stock is undervalued but becomes problematic if the long-term thesis deteriorates. Leverage is elevated (~3.5x EBITDA).